EPIX
Price:
$1.83
Market Cap:
$81.20M
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.[Read more]
Industry
Biotechnology
IPO Date
2015-03-13
Stock Exchange
NASDAQ
Ticker
EPIX
According to ESSA Pharma Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -2.95. This represents a change of -67.79% compared to the average of -9.16 of the last 4 quarters.
The mean historical PE Ratio of ESSA Pharma Inc. over the last ten years is -8.54. The current -2.95 PE Ratio has changed 3.36% with respect to the historical average. Over the past ten years (40 quarters), EPIX's PE Ratio was at its highest in in the September 2015 quarter at 22.70. The PE Ratio was at its lowest in in the September 2014 quarter at -36.98.
Average
-8.54
Median
-5.38
Minimum
-38.02
Maximum
-1.24
Discovering the peaks and valleys of ESSA Pharma Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 142.66%
Maximum Annual PE Ratio = -1.24
Minimum Annual Increase = -72.70%
Minimum Annual PE Ratio = -38.02
Year | PE Ratio | Change |
---|---|---|
2023 | -5.13 | 124.46% |
2022 | -2.28 | -72.70% |
2021 | -8.36 | 26.63% |
2020 | -6.61 | 142.66% |
2019 | -2.72 | 120.08% |
2018 | -1.24 | -34.06% |
2017 | -1.88 | -66.69% |
2016 | -5.63 | -58.34% |
2015 | -13.52 | -64.45% |
2014 | -38.02 | -24.78% |
The current PE Ratio of ESSA Pharma Inc. (EPIX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-5.26
5-year avg
-5.02
10-year avg
-8.54
ESSA Pharma Inc.’s PE Ratio is less than Altamira Therapeutics Ltd. (-0.03), greater than Summit Therapeutics Inc. (-70.20), less than Avenue Therapeutics, Inc. (-0.23), less than Spero Therapeutics, Inc. (21.41), less than Aeglea BioTherapeutics, Inc. (-0.20),
Company | PE Ratio | Market cap |
---|---|---|
-0.03 | $1.60M | |
-70.20 | $14.00B | |
-0.23 | $3.84M | |
21.41 | $63.24M | |
-0.20 | $48.63M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ESSA Pharma Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like ESSA Pharma Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is ESSA Pharma Inc.'s PE Ratio?
How is the PE Ratio calculated for ESSA Pharma Inc. (EPIX)?
What is the highest PE Ratio for ESSA Pharma Inc. (EPIX)?
What is the 3-year average PE Ratio for ESSA Pharma Inc. (EPIX)?
What is the 5-year average PE Ratio for ESSA Pharma Inc. (EPIX)?
How does the current PE Ratio for ESSA Pharma Inc. (EPIX) compare to its historical average?